Autologous TIL therapy is an immunotherapeutic approach that leverages the patient’s own immune system to combat malignant cells. TILs are lymphocytes naturally present within a tumor, harboring the innate capability to recognize cancer-specific antigens. The therapeutic process involves surgically extracting these lymphocytes from tumor biopsies, expanding them ex vivo to quantities often reaching into the hundreds of millions, and infusing them back into the patient. This infusion aims to augment the immune response by saturating the body with highly active, tumor-specific lymphocytes capable of targeting and dismantling cancer cells more effectively than the patient’s unassisted immune system.

The impetus for this trial stems from earlier observational studies indicating that higher levels of TILs within tumors correlate with improved disease-free survival rates among HNSCC patients. This established an immunological rationale for enhancing TIL presence therapeutically, particularly within the context of recurrent or metastatic disease where conventional therapies—such as chemotherapy, radiation, and surgery—have often failed. The phase 2 trial enrolled 53 patients categorized into four distinct treatment arms, which allowed for a comparative assessment of various TIL formulations. These included non-cryopreserved TILs, cryopreserved lifileucel—an FDA-approved T-cell therapy previously validated in metastatic melanoma—non-cryopreserved lifileucel, and a cryopreserved TIL therapy enriched for PD-1 positive cells. PD-1 is an immune checkpoint receptor commonly expressed on T cells, acting as a marker for tumor-reactive lymphocytes.

Participants in the study predominantly consisted of males, with a median age of 57 years, suffering from late-stage metastatic HNSCC. The median duration of treatment exposure was approximately 17.9 months, and the median response to therapy lasted 7.6 months, though some patients experienced disease stabilization for nearly two years. Impressively, 64% of patients across the cohorts achieved stabilization of cancer progression—a benchmark that, until this study, had been elusive for this clinical population. The median overall survival was reported to be 9.5 months, a figure that notably surpasses existing outcomes for similar patient groups who have exhausted standard care options.

Side effect profiles were consistent with expectations for TIL-based therapies, which can prompt systemic inflammatory responses due to lymphocyte activation. The most prevalent non-hematologic adverse events included chills, experienced in 60% of patients, hypotension in 53%, and fever in 47%. Hematologic toxicities manifested as thrombocytopenia and anemia, with incidences of 74% and 53%, respectively. These side effects, while notable, were generally manageable with supportive care. The trial’s safety data reinforce the feasibility of administering TIL therapies to this fragile cohort without incurring unacceptable toxicity.

Robert L. Ferris, MD, PhD, who led the investigation while at UPMC Hillman Cancer Center and subsequently analyzed the findings as executive director at UNC Lineberger, underscored the significance of the outcomes. Ferris highlighted that these patients usually have limited life expectancy due to aggressive disease and prior treatment failures. The approximate nine-month extension in survival attributable to TIL therapy represents a meaningful clinical breakthrough, underscoring the importance of immunotherapeutic strategies in refractory solid tumors.

Despite these encouraging results, Ferris and colleagues acknowledged challenges inherent to the therapy’s broader applicability. The relatively small patient populations in each treatment arm limited the ability to perform direct statistical comparisons, emphasizing the necessity for larger, randomized controlled trials to comprehensively ascertain efficacy. Furthermore, questions remain regarding the optimization of TIL manufacturing—whether fresh or cryopreserved cells yield superior clinical outcomes—as well as the identification of synergistic combination regimens that could potentiate anti-tumor effects while mitigating immune evasion.

Of particular interest is the enrichment for PD-1 positive TILs, leveraging the understanding that these cells bear markers of prior tumor engagement and potential exhaustion. Modulating this population through adjunctive therapies, such as immune checkpoint inhibitors, might amplify the therapeutic durability of TIL infusions. Exploring these combinations could usher in a new paradigm in HNSCC treatment, providing not just disease stabilization but meaningful regression and long-term remission.

Head and neck squamous cell carcinoma remains a significant clinical challenge worldwide, accounting for approximately 3.6% of all new cancers in the United States, with nearly 60,000 diagnoses anticipated in 2025 alone. The notoriously aggressive nature of metastatic HNSCC, combined with frequent resistance to chemo- and radiotherapies, underscores the urgency of novel immunotherapies. The present study’s findings affirm the potential of individualized cell-based immunotherapies to fill this critical therapeutic void.

Underlying the trial’s success was a collaboration with Iovance Biotherapeutics, the manufacturer of lifileucel, ensuring access to cutting-edge cell manufacturing technologies. Lifileucel’s prior approval for metastatic melanoma provided a precedent for its adaptation in HNSCC, and the current findings could expand the therapeutic indications for this biologic agent. Moving forward, the results pave the way for subsequent large-scale studies designed to evaluate TIL therapy head-to-head against current standards of care, possibly reshaping treatment algorithms within oncology.

As the field of cancer immunotherapy evolves, the implications of TIL therapy extend beyond head and neck cancers. Enhancing the precision of adoptive T-cell therapies, optimizing cell culture conditions, and refining patient selection criteria hold promise for improving outcomes across various malignancies. This trial stands as a landmark step, illuminating the path toward harnessing the patient’s own immune system to tackle some of the most intractable cancers known to medicine.

In summary, the phase 2 clinical trial of autologous TIL therapy in recurrent and metastatic head and neck squamous cell carcinoma offers a compelling narrative of hope and scientific rigor. With the therapy demonstrating a tangible survival benefit and manageable safety profile, the findings invigorate the quest for personalized immunotherapies. Future research is expected to focus on combination modalities, refined manufacturing processes, and randomized trials that will ultimately define the clinical utility of TIL therapy in oncology practice.

Subject of Research: People

Article Title: Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

News Publication Date: 24-Aug-2025

Web References:
https://jitc.bmj.com/lookup/doi/10.1136/jitc-2025-011633

Image Credits: UNC Lineberger Comprehensive Cancer Center

Keywords: Cancer, Immunology, Cancer immunology, Immunotherapy, Head and neck cancer, Lymphocytes

At the core of this partnership lies a comprehensive long-term strategy to integrate continuous immune profiling within CRI’s diverse portfolio of clinical trials. This initiative is designed to systematically track the dynamic interactions between novel immunotherapeutic agents and patient immune systems, aiming to reveal the molecular and cellular underpinnings that govern therapeutic efficacy. By dissecting these complex immune responses, researchers aspire to identify biomarkers predictive of treatment success, offering a tailored approach that maximizes patient benefit while minimizing ineffective interventions.

This collaboration was catalyzed by Dr. Thomas Marron, MD, PhD, Director of the Early Phase Trial Unit at Mount Sinai’s Tisch Cancer Institute and Chief Medical Officer of OCCAM Immune. Recognizing the complementary strengths and shared vision of Mount Sinai and CRI, Dr. Marron orchestrated this alliance to accelerate progress in immunotherapy research. His leadership emphasizes the importance of integrating clinical insights with cutting-edge immunological assays to unlock mechanistic knowledge that can inform next-generation therapeutic design.

“CRI’s decades-long expertise in cancer immunotherapy and global reach of clinical trial samples is invaluable,” Dr. Marron states. “OCCAM Immune brings to the table high-dimensional profiling technologies and the analytical acumen to convert extensive immunological data into actionable intelligence. Together, our combined efforts will unravel the nuances of immune engagement, enabling personalized immunotherapy regimens that are both precise and effective.”

Immunotherapy, a revolutionary modality that harnesses the body’s immune defenses to combat malignancy, has dramatically transformed cancer care. Nonetheless, its heterogeneous efficacy—where many patients exhibit resistance or relapse—underscores a critical need to elucidate the biological determinants of response. OCCAM Immune addresses this challenge by generating detailed immune maps before and during treatment, employing technologies such as RNA and DNA sequencing, single-cell immune phenotyping, and spatial transcriptomics to reveal the immune system’s configuration and dynamics with unprecedented resolution.

OCCAM Immune operates synergistically within Mount Sinai’s extensive medical and research framework. This includes collaborations with leaders like Dr. Miriam Merad, Dean for Translational Research and Therapeutic Innovation and Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM). Under her guidance, the division propels forward the frontiers of immunological research, integrating multi-omic data with clinical phenotypes to construct predictive models of immune behavior in cancer contexts. Through PrIISM, the initiative offers unparalleled access to rare human clinical samples and sophisticated analytical platforms that accelerate biomarker discovery and therapeutic innovation.

On the CRI side, Alicia Zhou, PhD, Chief Executive Officer, highlights how the fusion of OCCAM Immune’s advanced immune profiling capabilities with CRI’s extensive immunotherapy clinical network creates a potent synergy. "By leveraging our combined resources and expertise, we are not only hastening the pace of discovery but also edging closer to a future where personalized immunotherapy can be delivered with greater precision and confidence, improving patient outcomes worldwide," Zhou remarks.

The collaboration’s inaugural project targets a clinical trial focused on ovarian cancer, specifically platinum-resistant high-grade serous ovarian carcinoma—a notoriously aggressive subtype with high relapse rates. By meticulously scrutinizing immune cells and tumor biopsies from enrolled patients, the research team aims to delineate the immune landscapes shaped by novel drug combinations. The analysis will incorporate advanced techniques like deep RNA/DNA sequencing and multi-dimensional immune cell mapping, spanning approximately 160 patient-derived samples, to decode the molecular signatures linked to therapeutic resistance and sensitivity.

Dr. Merad underscores the broader implications of this scientific endeavor: “This partnership exemplifies the growing recognition of our capacity to deliver high-fidelity immune data critical to advancing personalized medicine and AI-driven drug development. By converging expertise across academic, biotech, and pharmaceutical sectors, we are poised to unlock the full potential of the immune system, transforming cancer care and improving patient survival rates.”

OCCAM Immune stands at the intersection of academic research and clinical application, specializing in the identification of immune biomarkers that predict and monitor response trajectories to immunotherapies. By leveraging state-of-the-art profiling platforms and computational tools, the organization supports academia, industry, and nonprofit partners in optimizing immunotherapy protocols and enhancing the design and outcomes of clinical trials addressing cancer, autoimmune disorders, allergies, and infectious diseases.

Founded in 1953, the Cancer Research Institute remains steadfast in its mission to propel immunotherapy from experimental intervention to standard-of-care treatment across all cancer types. By funding global researchers and facilitating patient access to innovative clinical trials through its Cancer Immunotherapy Clinical Trial Finder, CRI plays a pivotal role in translating scientific insights into tangible clinical benefits, fostering a future where cancer becomes a manageable or curable disease.

The Icahn School of Medicine at Mount Sinai, home to OCCAM Immune and the Tisch Cancer Institute, is a beacon of biomedical innovation. It hosts a vibrant academic and clinical community committed to pushing the boundaries of translational research. Through Mount Sinai Innovation Partners (MSIP), the institution actively accelerates the commercialization of groundbreaking medical discoveries, ensuring that laboratory breakthroughs rapidly evolve into clinical advancements that save lives.

This collaboration heralds a critical inflection point in the fight against cancer—one where comprehensive immune monitoring, integrative data analysis, and collaborative research converge to create the toolkit necessary for precision immunotherapy. As cancer treatment continues to evolve, such alliances underscore the imperative of bridging disciplines and institutions, ultimately translating scientific discovery into improved patient care on a global scale.

Subject of Research: Immune system monitoring and response to advanced cancer immunotherapies, specifically in platinum-resistant high-grade serous ovarian cancer.

Article Title: Mount Sinai’s OCCAM Immune and Cancer Research Institute Unite to Revolutionize Cancer Immunotherapy Through Advanced Immune Monitoring

News Publication Date: June 17, 2025

Web References:

• Thomas Marron Profile
• The Tisch Cancer Institute
• Miriam Merad lab
• Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM)
• National Cancer Institute-Designated Cancer Centers

Keywords: Cancer immunology, immunotherapy, immune monitoring, precision oncology, ovarian cancer, platinum-resistant cancer, immune cell mapping, RNA sequencing, DNA sequencing, biomarker discovery, personalized medicine, immuno-oncology.